Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12308700 | 0.85 | XPNPEP2 (0.40) | SMN1; SMN2ALDH1A1MAPK1GRM3CREBBP | |
| SCHEMBL12335980 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1MAPK1LMNAGRM3 | |
| SCHEMBL12334769 | 0.81 | LMNA (0.47) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11922963 | 0.79 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1MAPK1LMNAGRM3 | |
| SCHEMBL28447168 | 0.79 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1MAPK1LMNAGRM3 | |
| SCHEMBL12334751 | 0.78 | KMT2A (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL12308794 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1MAPK1LMNAGRM3 | |
| SCHEMBL12334765 | 0.76 | L3MBTL1 (0.39) | ALDH1A1MEN1KMT2A | |
| SCHEMBL12182476 | 0.76 | MEN1 (0.58) | SMN1; SMN2ALDH1A1MAPK1LMNACREBBP | |
| SCHEMBL12334750 | 0.74 | GNAI3 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017638-B2 | Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 | SHIONOGI & CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | HSD3B1, NR5A1, HSD11B1 | SMN1; SMN2 4090/4885ALDH1A1 203/4885MAPK1 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.